



Experience
INDIAN
HEALTHCARE

Poly Medicure Ltd.

Regd. Office : 232-B, 3rd Floor, Okhla Industrial Estate, Phase - III, New Delhi - 110020, INDIA
Tel : +91-11-47317000, 33550700, 26321838 / 81 / 89 / 93 / 99, Fax : +91-11-26321894, 26321839
E-mail : info@polymedicure.com Website : www.polymedicure.com
CIN : L40300DL1995PLC066923

POLYMED
Medical Devices

Date: 12th August, 2017

Scrip Code: - 531768

Scrip Code:- POLYMED

The Manager,
Bombay Stock Exchange Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Subject: Outcome of the Board Meeting of the Company

Ref: Compliance of Regulation 30 and 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 12th August, 2017, at Crowne Plaza Hotels, Community Center, Okhla Phase-I, New Delhi - 110020, approved the following businesses:

- Un-Audited Financial Results along with Limited Review Report for the first quarter ended on 30th June, 2017.
- Other Normal Business.

Kindly take a note of the same for your further needful and oblige us.

Thanking You,

Yours Sincerely

For Poly Medicure Limited


Avinash Chandra
Company Secretary



₹ in lacs

	Particulars	Standalone	
		Quarter ended	
		30.06.2017	30.06.2016
		(Unaudited)	
1	Income		
a	Net sales / income from operations (Inclusive of excise duty)	10,866.45	10,395.94
b	Other income	364.71	230.60
	Total income	11,231.16	10,626.54
2	Expenses		
a	Cost of materials consumed	3,786.37	3,565.05
b	Purchases of stock-in-trade	113.41	171.90
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(710.69)	(253.93)
d	Excise Duty on Sales	126.10	146.66
e	Employee benefits expense	2,117.73	1,984.05
f	Research and development expenses	244.69	252.48
g	Finance cost	210.65	228.37
h	Depreciation and amortisation expense	653.69	533.09
i	Other expenses	2,873.45	2,211.36
	Total expenses	9,415.38	8,839.03
3	Profit from operations before exceptional items (1-2)	1,815.78	1,787.51
4	Exceptional Items	-	-
5	Profit before tax	1,815.78	1,787.51
6	Tax expense		
a	Current tax	668.02	505.05
b	Deferred tax	(54.39)	21.97
	Total Tax Expenses	613.63	527.02
7	Profit for the period	1,202.15	1,260.50
8	Other Comprehensive Income		
	Items that will not be reclassified to profit or loss	(7.63)	(5.09)
	Tax Impacts on above	2.64	1.76
	Total Other Comprehensive Income	(4.99)	(3.33)
9	Total comprehensive income (comprising profit after tax and other comprehensive income after tax for the period)	1,197.16	1,257.17
10	Earnings per share (Quarterly not annualised) :		
	Basic (₹)	1.36	1.42
	Diluted (₹)	1.36	1.42
11	Paid-up equity share capital (Face Value of ₹ 5 each)	4,411.34	2,205.67



Notes:

- 1 The above results were reviewed and recommended by the Audit Committee & approved by the Board of Directors at their respective meetings held on August 12, 2017. The financial results for the quarter ended June 30, 2017 have been limited reviewed by the Statutory Auditors of the Company.
- 2 The standalone financial results have been prepared in accordance with the principles and procedures of Indian Accounting Standards ("Ind AS") as notified under the Companies (Indian Accounting Standards) Rules, 2015 as specified in Section 133 of the Companies Act, 2013.
- 3 The Company has adopted Ind AS from April 1, 2017 and accordingly, these consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder. The date of transition to Ind AS is April 1, 2016. The impact of transition has been accounted for in the opening reserves and the comparative period results have been restated accordingly. The opening balance sheet as at April 1, 2016 and the results for the subsequent periods would be finalised and will be subject to audit at the time of annual financial statements for the year ended March 31, 2018.
- 4 In line with the provisions of Ind AS 108 – Operating Segments and on the basis of review of operations being done by the management of the Company, the operations of the group falls under medical devices, which is considered to be the only reportable segment by the management.
- 5 Reconciliation of Net Profit after tax as previously reported under Indian GAAP and Ind AS for the quarter ended June 30, 2016 is as under:-

Particulars	₹ in lacs
	Standalone
Net profit as per previous Indian GAAP	1,266.38
Impact of adjustment in defined benefit obligation	5.09
Impact of measurement of financial assets and liabilities at amortised cost (Net)	(0.22)
Impact of forward contract accounting / exchange differences (Net)	(12.95)
Other Miscellaneous adjustments	(0.92)
Deferred tax impact on above adjustments	3.11
Net profit for the period under Ind AS	1,260.50
Other Comprehensive Income / (Loss)	(3.33)
Total Comprehensive Income as per Ind AS	1,257.17


The above reconciliation of net profit after tax under Ind AS of the corresponding quarter with net profit reported under previous GAAP has been reported by the management and have not been subject to limited review or audit.

- 6 The standalone financial results for the quarter ended June 30, 2016 are also Ind AS compliant. The management has exercised necessary due diligence to ensure that the standalone financial results give a true and fair view. This information has not been subjected to limited review or audit.
- 7 The Company has opted to publish standalone financial results for the quarter ended June 30, 2017 and the consolidated financial results shall be published for the quarter / year ending March 31, 2018.
- 8 EPS for the quarter ended June 30, 2016 have been restated pursuant to bonus issue in quarter ended March 31, 2017.
- 9 The standalone unaudited financial results of the Company for the quarter ended June 30, 2017 are also available on the Company's Website (www.polymedicure.com) and on the Website of BSE (www.bseindia.com) and NSE (www.nseindia.com).

Place : New Delhi
Date : 12.08.2017



Himanshu Baid
Himanshu Baid
Managing Director



	Particulars	Standalone Qtr. Ended	
		30.06.2017	30.06.2016
		(Unaudited)	
1	Total Income from operations	11,231.16	10,626.54
2	Net Profit from ordinary activities after tax	1,202.15	1,260.50
3	Net Profit for the period after tax (after Extraordinary items)	1,202.15	1,260.50
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(4.99)	(3.33)
5	Equity paidup share capital	4,411.34	2,205.67
6	Earnings per share (Quarterly not annualised) :		
	Basic (₹)	1.36	1.42
	Diluted (₹)	1.36	1.42

1. The above results were reviewed and recommended by the Audit Committee & approved by the Board of Directors at their respective meetings held on August 12, 2017. The financial results for the quarter ended June 30, 2017 have been limited reviewed by the Statutory Auditors of the Company.

2. EPS for the quarter ended June 30, 2016 have been restated pursuant to bonus issue in quarter ended March 31, 2017.

3. The above is an extract of the detailed format of unaudited standalone Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited standalone Financial Results are available on the Stock Exchange websites, www.bseindia.com, www.nseindia.com and on the company website www.polymedicure.com

Place : New Delhi
Date : 12.08.2017



Himanshu Baid
Managing Director

DOOGAR & ASSOCIATES

Chartered Accountants

LIMITED REVIEW REPORT

To Board of Directors
Poly Medicure Limited
232-B, IIIrd Floor,
Okhla Industrial Estate, Phase-III,
New Delhi- 110020

We have reviewed the accompanying statement of unaudited standalone financial results of Poly Medicure Limited ("the company") for the quarter ended 30th June, 2017 attached herewith, being submitted by the company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). Attention is drawn to the fact that the figures for the corresponding quarter ended 30th June, 2016 including the reconciliation of profit under Ind AS of the corresponding quarter with profit reported under previous GAAP, as reported in these financial results have been approved by company's Board of Directors but have not been subjected to review. This statement is the responsibility of the Company's Management and approved by the Board of Directors has been compiled from the related interim financial statements which has been prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place of signature : New Delhi
Date: 12th Aug 2017

For Doogar & Associates
Chartered Accountants
Firm Registration No. 000561N


M. S. Agarwal
Partner
Membership No. 86580

